The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.

@article{Li2014ThePO,
  title={The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.},
  author={Rui-chao Li and Li-jun Zheng and Ming-hao Fang and Shi-ying Yu},
  journal={The International journal of biological markers},
  year={2014},
  volume={29 2},
  pages={e112-9}
}
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. The presence of EGFR mutations was previously shown to confer sensitivity to TKIs. In this study, we evaluated the correlation between EGFR… CONTINUE READING